ReviewCellular oncology (Dordrecht, Netherlands)2026
The influence of cell-cell fusion on cancer heterogeneity and its promise for targeted treatments.
Review in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Zeb1 Is a Determinant of EMT in Human MDA-MB-231 Breast Cancer Cells and M13-MDA231 Tumor Hybrids.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-cell fusion is a common cellular process that occurs in nature. In the physiological environment, cell-cell fusion plays a crucial role in the establishment of homeostasis and the normal development of an organism. Normal cell-cell fusion is related to zygote formation, placental development, muscle growth, and macrophage formation. However, in cancer, cell-cell fusion destabilizes homeostasis and enhances cancer heterogeneity. The fusion of cancer and normal host cells, such as mesenchymal stem cells or white blood cells, promotes cancer growth, metastasis, and immune escape. On the other hand, fusion of cancer cells with each other leads directly to the formation of polyploid giant cancer cells (PGCCs). PGCCs are cancer stem cells considered the root cause of cancer metastasis, chemoradiotherapy resistance and recurrence. The presence of PGCCs significantly promotes the evolution of cancer. Clinical detection and targeted therapies based on cell-cell fusion have rapidly emerged with advancements in cell culture technology, which may bring hope to the treatment of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.